Saturday 17 October 2026
Export VERA’s income statement to Excel — free account
Vera Therapeutics, Inc.
VERA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 26.7%, free cash flow fell 82.5% and total debt rose 1.03%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
27.88
0.69
−2.42%
Follow VERA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(73.25%) | (50.71%) | (71.32%) | (91.75%) | |
| (56.87%) | (43.10%) | (59.90%) | (72.32%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(53.54%) | (44.27%) | (64.65%) | (83.87%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(3.31) | (3.76) | (4.11) | (4.72) | |
Free Cash Flow |
(211.46) | (241.73) | (293.66) | (338.91) | |
Capital Expenditures |
(1.17) | (0.63) | (0.47) | (0.26) | |
| Other line items | |||||
Cash ROIC |
(21.78%) | (17.34%) | (25.07%) | (34.51%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(36.03) | (41.89) | (50.70) | (55.17) | |
Operating CF/Net income |
0.83 | 0.80 | 0.79 | 0.84 | |
Depreciation/Fixed assets |
(5.29) | (3.39) | 0.00 | 0.00 | |
Capex/Depreciation |
0.19 | 0.14 | 0.19 | 0.22 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.29) | (3.75) | (4.10) | (4.71) | |
Capex per Share |
(0.02) | (0.01) | (0.01) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates